ArticleCancers2021
Primary Effusion Lymphoma: A Clinicopathological Study of 70 Cases.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Fluid overload-associated large B-cell lymphoma: two case report and review of literature.Frontiers in oncology · 2025Pooled it
- Extracavitary Primary Effusion Lymphoma: Diagnostic Challenges and Differential Diagnosis in a Resource-Constrained South African Setting.International journal of surgical pathology · 2026Article
- Real-World Application of the WHO Reporting System for Lymph Node Cytopathology in the Context of the 5th Edition of the WHO Classification of Hematolymphoid Neoplasms.Acta cytologica · 2026Review
- A Critical Role for Epstein-Barr Virus in Primary Effusion Lymphoma.Current topics in microbiology and immunology · 2025Article
- An Unusual Case of Extracavitary/Solid Variant Primary Effusion Lymphoma With Associated Hemophagocytic Lymphohistiocytosis.Journal of medical cases · 2025Article
- Review
- Extracavitary primary effusion lymphoma presenting as a solitary brain mass.CNS oncology · 2024Article
- EBV-Positive Nodal T- and NK-Cell Lymphoma Mimicking Anaplastic Large Cell Lymphoma: A Case Report.Hematology reports · 2024Article
- Molecular Features of HHV8 Monoclonal Microlymphoma Associated with Kaposi Sarcoma and Multicentric Castleman Disease in an HIV-Negative Patient.International journal of molecular sciences · 2024Article
- Promising immunotherapeutic approaches for primary effusion lymphoma.Exploration of targeted anti-tumor therapy · 2024Review
- Cavity-based lymphomas: challenges and novel concepts. A report of the 2022 EA4HP/SH lymphoma workshop.Virchows Archiv : an international journal of pathology · 2023Article
- Primary Effusion Lymphoma: A Rare and Challenging Diagnosis for Recurrent Pleural Effusion.Diagnostics (Basel, Switzerland) · 2023Article
- Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease.Oncoimmunology · 2023Article
- Targeting VEGF with bevacizumab inhibits malignant effusion formation of primary human herpesvirus 8-unrelated effusion large B-cell lymphoma in vivo.Journal of cellular and molecular medicine · 2022Article
- Article
- Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma.Cancer immunology, immunotherapy : CII · 2022Article
- Synchronous visceral Kaposi sarcoma and extracavitary primary effusion lymphoma in a patient with AIDS.BMJ case reports · 2022Article
- Primary Effusion Lymphoma: A Timely Review on the Association with HIV, HHV8, and EBV.Diagnostics (Basel, Switzerland) · 2022Review
- Review
- Classic KSHV/HHV-8-positive Primary Effusion Lymphoma (PEL): A Systematic Review and Meta-Analysis of Case Reports.Mediterranean journal of hematology and infectious diseases · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 10 institutions in 1 country.
Funding
Abstract
Primary effusion lymphoma (PEL) is a rare type of large B-cell lymphoma associated with human herpesvirus 8 (HHV8) infection. Patients with PEL usually present with an effusion, but occasionally with an extracavitary mass. In this study, we reported a cohort of 70 patients with PEL: 67 men and 3 women with a median age of 46 years (range 26-91). Of these, 56 (80%) patients had human immunodeficiency virus (HIV) infection, eight were HIV-negative, and six had unknown HIV status. Nineteen (27%) patients had Kaposi sarcoma. Thirty-five (50%) patients presented with effusion only, 27 (39%) had an extracavitary mass or masses only, and eight (11%) had both effusion and extracavitary disease. The lymphoma cells showed plasmablastic, immunoblastic, or anaplastic morphology. All 70 (100%) cases were positive for HHV8. Compared with effusion-only PEL, patients with extracavitary-only PEL were younger (median age, 42 vs. 52 years,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.